Insight into the behavior of hairy cell leukemia by immunogenetic analysis

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 2, 2011, Pages 103-107

  Forconi, Francesco ^a   Cencini, Emanuele ^a   Sozzi, Elisa ^a   Sicuranza, Anna ^a   Raspadori, Donatella ^a   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

cladribine; Hairy cell leukemia; IGH; immunogenetics; prognosis

Indexed keywords

B LYMPHOCYTE RECEPTOR; CLADRIBINE; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; NUCLEIC ACID BINDING PROTEIN; PROTEIN P53; PROTEIN RAG; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL MATURATION; CLINICAL FEATURE; GENETIC ANALYSIS; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOGENETICS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SOMATIC MUTATION; TREATMENT RESPONSE;

CLADRIBINE; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, HAIRY CELL; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL;

EID: 79957455041     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.569620     Document Type: Article

References (51)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609-630.
2. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869-1870.
3. Forconi F, Raspadori D, Lenoci M, Lauria F. Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica 2005;90:266-268. (Pubitemid 40293296)
4. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p 441.
5. Rajewsky K, von Boehmer H. Lymphocyte development:overview. Curr Opin Immunol 2008;20:127-130.
6. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res 2001;83:81-116. (Pubitemid 32959263)
7. Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol 2006;133:504-512.
8. Thorselius M, Walsh SH, Thunberg U, Hagberg H, Sundstrom C, Rosenquist R. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. Leuk Res 2005;29:153-158. (Pubitemid 39647509)
9. Forconi F, Sozzi E, Rossi D, et al. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica 2008;93: 697-705. (Pubitemid 351669309)
10. Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696-4702.
11. Maloum K, Magnac C, Azgui Z, et al. VH gene expression in hairy cell leukaemia. Br J Haematol 1998;101:171-178. (Pubitemid 28197791)
12. Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood 2001;98:1174-1181.
13. Vanhentenrijk V, Tierens A, Wlodarska I, Verhoef G, Wolf- Peeters CD. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia 2004;18:1729-1732. (Pubitemid 39386355)
14. Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood 2004;104:3312-3317. (Pubitemid 39507151)
15. Kayano H, Dyer MJ, Zani VJ, et al. Aberrant rearrangements within the immunoglobulin heavy chain locus in hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl. 1):41-47. (Pubitemid 24282592)
16. Haak HL, de Man JC, Hijmans W, Speck B. Further evidence for the lymphocytic nature of leukaemic reticuloendotheliosis (hairy-cell leukaemia). Br J Haematol 1974;27:31-38.
17. Burns GF, Cawley JC, Worman CP, et al. Multiple heavy chain isotypes on the surface of the cells of hairy cell leukemia. Blood 1978;52:1132-1147. (Pubitemid 9071621)
18. Golomb HM, Davis S, Wilson C, Vardiman J. Surface immunoglobulins on hairy cells of 55 patients with hairy cell leukemia. Am J Hematol 1982;12:397-401. (Pubitemid 12073156)
19. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993;82:1277-1287. (Pubitemid 23254004)
20. Sozzi E, Amato T, Sahota SS, et al. Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia. Hematol Oncol 2011;29:31-37.
21. Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006;6:437-448.
22. Berek C. The development of B cells and the B-cell repertoire in the microenvironment of the germinal center. Immunol Rev 1992;126:5-19.
23. MacLennan IC, Toellner KM, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev 2003;194: 8-18. (Pubitemid 36886424)
24. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
25. Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 2004;5:1523-1533. (Pubitemid 39029033)
26. Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl. 1):121-125. (Pubitemid 24282606)
27. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-896. (Pubitemid 46606450)
28. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-740.
29. Kreitman RJ. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 2009;15:2652-2664.
30. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658-4662. (Pubitemid 43882611)
31. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27: 2983-2990.
32. Lauria F, Forconi F. Combination therapies to improve the long-term outcome in hairy cell leukemia. Leuk Lymphoma 2009;50(Suppl. 1):18-22.
33. Dearden C, Else M. Hairy cell leukemia. Curr Oncol Rep 2006;8:337-342. (Pubitemid 44336296)
34. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994;83: 3672-3681. (Pubitemid 24175558)
35. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994;120:784-791. (Pubitemid 24125300)
36. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810-813. (Pubitemid 36917768)
37. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004;89:309-313. (Pubitemid 38788415)
38. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442-2448. (Pubitemid 41691566)
39. Forconi F, Poretti G, Kwee I, et al. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. Br J Haematol 2008;141:622-630. (Pubitemid 351667631)
40. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446-5456.
41. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389-4395. (Pubitemid 38745961)
42. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
43. Pettitt AR, Sherrington PD, Cawley JC. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999;106:1049-1051. (Pubitemid 29463023)
44. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967. (Pubitemid 23289454)
45. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008;112:3322-3329.
46. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall Survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
47. Kienle D, Krober A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003;102:3003-3009. (Pubitemid 37248876)
48. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101:4975-4981. (Pubitemid 36857762)
49. Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003;21:3928-3932. (Pubitemid 46606205)
50. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-1416. (Pubitemid 34864299)
51. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4- 34\+hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-4695.